{"filings":[{"id":1314643,"accession_number":"0001193125-26-286273","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2026-06-26T22:18:31+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Viridian Therapeutics receives FDA approval for Lumvoa (veligrotug-vvze) to treat thyroid eye disease","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Lumvoa is the first FDA-approved treatment for TED with labeling covering both active and chronic disease.","Approval supported by positive Phase 3 THRIVE and THRIVE-2 trials meeting primary and all secondary endpoints.","Lumvoa showed statistically significant improvement in diplopia response and complete resolution in active and chronic TED.","Viridian plans to launch Lumvoa immediately with a comprehensive patient support program (ViridianCares).","Company will host a conference call on June 29, 2026, at 8:00 a.m. ET to discuss the approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":815401,"accession_number":"0001193125-26-254560","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2026-06-03T11:00:22+00:00","items":["5.07"],"status":"ready","headline":"Viridian Therapeutics Annual Meeting approves director elections, KPMG ratification, say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Tomas Kiselak and Jennifer K. Moses elected as Class II directors until 2029.","KPMG LLP ratified as independent auditor for FY2026; 92.9M for, 0.5M against.","Advisory say-on-pay approved with 83.5M for, 3.1M against.","Board sets future say-on-pay votes every year based on advisory vote results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":721813,"accession_number":"0001193125-26-245186","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2026-05-28T20:05:08+00:00","items":["1.02"],"status":"ready","headline":"Viridian pre-pays $55.1M Hercules Capital loan, terminates credit facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Paid ~$55.1M to satisfy all principal, accrued interest and fees under Loan Agreement with Hercules Capital.","Original term loan allowed up to $300M; company borrowed $50M at floating rate (min 8.95%, cap 9.45%).","Loan termination effective May 27, 2026; all obligations discharged and covenants eliminated.","Interest-only payments were due through Oct 2029/2030 depending on milestones; now fully extinguished."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":667523,"accession_number":"0001193125-26-239246","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2026-05-26T20:05:16+00:00","items":["1.01"],"status":"ready","headline":"Viridian inks commercial manufacturing deal with WuXi Biologics for veligrotug","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement covers long-term supply of veligrotug drug substance and drug product, if approved.","WuXi Biologics is non-exclusive supplier; Viridian may use alternate manufacturers.","Initial term of 5 years, auto-renewing for successive 5-year periods unless 24-month non-renewal notice given.","Volume-based pricing fixed through Dec 31, 2026, then annually adjustable; pass-through costs reimbursed.","Company may terminate on 30 days' notice for change in law materially impacting WuXi's performance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":12766,"accession_number":"0001193125-26-216709","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2026-05-11T20:02:12+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Viridian raises ~$359M via $250M convertible notes and $117M equity offering","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $250M aggregate principal of 1.75% Convertible Senior Notes due 2032; initial conversion price ~$24.65/share.","Equity offering of 7,352,942 shares at $17.00/share, netting ~$117M.","Combined net proceeds ~$359M; to repay Hercules Capital debt, fund thyroid eye disease franchise expansion, and R&D.","Both offerings closed May 11, 2026; underwriters' over-allotments exercised in full.","Notes are unsecured, mature May 15, 2032, with semi-annual interest starting Nov 15, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93923,"accession_number":"0001193125-26-205099","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Elegrobart Phase 3 REVEAL-2 meets primary endpoint; proptosis responder rate 50-54% vs 15% placebo (p<0.0001)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proptosis responder rate at week 24: 50% (Q4W) and 54% (Q8W) vs 15% placebo; both p<0.0001.","Diplopia responder rate 61% (Q4W) vs 38% placebo (p=0.0118); complete resolution 44% vs 25% (p=0.0295).","Elegrobart well tolerated; 91% completed treatment, no treatment-related SAEs, low hearing impairment rates.","BLA submission for elegrobart on track for Q1 2027; veligrotug PDUFA target action date June 30, 2026.","Second positive Phase 3 trial for elegrobart; supports potential first subcutaneous autoinjector for TED."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93922,"accession_number":"0001193125-26-205010","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viridian Q1 net loss $104.9M; veligrotug PDUFA June 30, elegrobart positive data, BLA Q1 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $762.2M at March 31, 2026, down from $874.7M at Dec 31, 2025; net loss $104.9M vs $86.9M YoY.","Veligrotug BLA under Priority Review with PDUFA target June 30, 2026; launch-ready with hired field teams.","Elegrobart (subcutaneous) met primary endpoints in REVEAL-1 (active TED) and REVEAL-2 (chronic TED); proptosis responder rates 50-63% vs 15-18% placebo.","BLA for elegrobart expected Q1 2027; MAA for veligrotug submitted to EMA and accepted for review.","SG&A jumped to $38.7M from $17.1M due to commercial prep; R&D flat at $77.6M."],"consensus_eps_estimate":-1.1162,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":141000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105920,"accession_number":"0001193125-26-130433","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Viridian Therapeutics announces positive phase 3 topline results for elegrobart in active thyroid eye disease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["REVEAL-1 met primary endpoint with 54% proptosis responder rate for elegrobart Q4W vs 18% placebo at week 24 (p<0.0001).","Elegrobart Q8W achieved 63% proptosis responder rate vs 18% placebo at week 24.","Complete resolution of diplopia in 51% of Q4W patients vs 16% placebo at week 24.","BLA submission for elegrobart anticipated in Q1 2027; REVEAL-2 top-line data expected Q2 2026.","Company ended Q4 2025 with $875M cash; veligrotug PDUFA date June 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105919,"accession_number":"0001193125-26-073391","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viridian reports 2025 net loss of $342.6M; veligrotug PDUFA date June 30, 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities were $874.7M as of Dec 31, 2025, up from $717.6M.","Net loss for 2025 was $342.6M ($269.9M in 2024); R&D spend rose to $338.9M.","PDUFA target action date for veligrotug BLA is June 30, 2026; Priority Review ongoing.","MAA for veligrotug submitted to EMA in January 2026 for European approval.","Phase 3 REVEAL-1 topline data for elegrobart on track for Q1 2026; REVEAL-2 for Q2 2026."],"consensus_eps_estimate":-1.0905,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":70849000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122184,"accession_number":"0001193125-25-265711","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viridian closes $289M equity, $300M royalty financing; BLA submitted for veligrotug in TED","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash position ~$887.9M as of Oct 31, 2025, up from $490.9M at Sep 30, after equity, royalty, and debt financings.","BLA for veligrotug (IV) in thyroid eye disease submitted to FDA Oct 2025 with Priority Review request; mid-2026 launch targeted if approved.","Subcutaneous VRDN-003 topline data accelerated: REVEAL-1 in Q1 2026, REVEAL-2 in Q2 2026; both trials exceeded enrollment targets (132 and 204 patients).","R&D expenses $86.3M in Q3 2025 (up 25% YoY) driven by Ph3 programs; G&A $24.3M (up 69% YoY) from launch prep.","VRDN-006 showed IgG reduction proof-of-concept in Ph1; VRDN-008 IND on track for year-end 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122183,"accession_number":"0001193125-25-247410","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Viridian Therapeutics priced 11.4M-share offering at $22/sh for ~$251M gross proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 11,425,000 shares at $22.00/share; underwriters have 30-day option for up to 1,713,750 additional shares.","Gross proceeds of ~$251.35M before underwriting discounts and expenses; closing expected October 23, 2025.","Net proceeds combined with existing cash, $70M Kissei upfront (Q4 2025), $55M DRI payment, $115M potential DRI milestones, and $30M term loan to fund operations.","Company assumes revenue from veligrotug and VRDN-003 if approved on anticipated timelines to extend cash runway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122182,"accession_number":"0001193125-25-245206","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Viridian expects ~$490.9M cash as of Sept 30, 2025; preliminary, unaudited","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, equivalents, and marketable securities of ~$490.9M as of September 30, 2025.","Figure is unaudited and may materially differ from final Q3 2025 balance sheet upon close.","Full Q3 2025 financial results not yet finalized; no revenue or EPS guidance provided.","Disclosure intended to provide early liquidity visibility ahead of complete financial report."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122181,"accession_number":"0001193125-25-243039","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Viridian Therapeutics secures up to $600M via royalty sale and debt facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DRI Healthcare pays $55M upfront for U.S. revenue rights; up to $300M total tied to VRDN-003 milestones and FDA approval.","Tiered royalties on veligrotug/VRDN-003 net sales: 7.5% up to $600M, then declining to zero above $2B.","Hercules Capital provides $300M term loan facility; $50M drawn at close, with tranches up to $300M depending on milestones.","Loan bears interest at prime+1.45% (floor 8.95%, cap 9.45%), maturity 2030, interest-only through 2029/2030.","Combined financing strengthens balance sheet for pivotal clinical trials and pre-commercial activities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138908,"accession_number":"0001193125-25-173983","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viridian reports cash of $563.4M; BLA for veligrotug on track for 2H 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and short-term investments $563.4M as of June 30, 2025, down from $636.6M at March 31, 2025; runway into 2H 2027.","R&D expenses $86.6M in Q2 2025 (up from $56.2M in Q2 2024) driven by more clinical trials and higher headcount.","Veligrotug BLA submission on track for 2H 2025; U.S. commercial launch anticipated in 2026 if approved.","Exclusive license with Kissei for Japan: $70M upfront, up to $315M in milestones, plus tiered royalties.","Veligrotug durability data: 70% of proptosis responders at week 15 maintained response at week 52."],"consensus_eps_estimate":-1.0296,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":147000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138907,"accession_number":"0001193125-25-168614","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Viridian Therapeutics licenses veligrotug, VRDN-003 to Kissei for Japan; $70M upfront, up to $315M milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront payment of $70M; up to $315M in development, regulatory, and commercial milestones.","Tiered royalties on Japan net sales in the 20s to mid-30s percent range.","Kissei gets exclusive Japan rights; Viridian retains manufacturing/supply responsibilities except limited cases.","Veligrotug (VRDN-001) and VRDN-003 are anti-IGF-1R antibodies targeting thyroid eye disease.","THRIVE and THRIVE-2 phase 3 trials for veligrotug met all primary and secondary endpoints."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156392,"accession_number":"0001193125-25-145741","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Viridian shareholders approve 8M-share increase in equity plan in close vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders narrowly approved amendment to increase equity plan shares by 8,000,000 (35.3M for, 35.1M against).","Three Class I directors elected: Jeff Ajer, Chris Cain, Sarah Gheuens.","Ratification of KPMG as auditor, advisory say-on-pay, and 2025 ESPP all passed.","Close 49.8% opposition on equity plan reflects significant shareholder dissent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156391,"accession_number":"0001193125-25-122821","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Viridian: 70% of veligrotug proptosis responders maintain response at week 52 in THRIVE trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["70% of veligrotug proptosis responders (21/30) in THRIVE maintained response at week 52, defined as ≥2 mm reduction from baseline without fellow eye worsening.","Safety profile unchanged in follow-up; majority of adverse events resolved by week 52.","BLA submission for veligrotug in TED on track for H2 2025; company preparing for potential U.S. launch in 2026.","Veligrotug received Breakthrough Therapy Designation, supporting Priority Review eligibility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156390,"accession_number":"0001193125-25-113291","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viridian Q1 cash $636.6M; veligrotug BLA on track for H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, and short-term investments $636.6M at March 31, 2025, down from $717.6M in December 2024; runway into H2 2027.","R&D expenses $76.8M in Q1 2025 vs $40.9M in Q1 2024, driven by more clinical trials and increased headcount.","Veligrotug BLA submission to FDA on track for H2 2025; EMA MAA expected in H1 2026.","Phase 3 topline data for VRDN-003 (subcutaneous TED) expected H1 2026 from REVEAL-1 and REVEAL-2 trials.","VRDN-006 phase 1 healthy volunteer data expected Q3 2025; VRDN-008 IND submission targeted for year-end 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":72000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156389,"accession_number":"0001193125-25-073937","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Viridian appoints Jeff Ajer to board; grants stock options to 14 new employees","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeff Ajer, former BioMarin CCO with 25+ years rare disease experience, appointed to VRDN board effective April 7, 2025.","Ajer led launches of 5 brands at BioMarin; will support veligrotug BLA submission and potential commercial launch.","Compensation Committee approved inducement grants of options for 220,750 shares to 14 new employees on April 1, 2025.","Options vest over 4 years (25% at one-year anniversary, then monthly), exercise price equals closing price on grant date.","Appointment strengthens board as Viridian advances veligrotug and FcRn portfolio toward regulatory milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174827,"accession_number":"0001193125-25-050880","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Viridian Therapeutics appoints Christopher Cain to board; Peter Harwin resigns effective March 10","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christopher Cain (Director of Research, Fairmount Funds Management) named Class I director and chair of Nominating and Corporate Governance Committee.","Peter Harwin resigned from the board effective March 10, 2025, with no disagreement with the company.","Cain also joins the Audit Committee and Science & Technology Committee; standard director compensation applies.","Cain previously served at Samsara BioCapital, Apple Tree Partners, RA Capital Management, and BioCentury."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174826,"accession_number":"0001193125-25-044406","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Viridian Therapeutics enters $300M ATM equity offering with Jefferies; terminates prior $175M ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New Open Market Sale Agreement with Jefferies LLC allows sale of up to $300M in common stock.","Proceeds to fund clinical development of veligrotug and other candidates, plus commercialization preparation.","Prior $175M ATM agreement terminated; $115.2M of shares sold under it.","Jefferies will receive up to 3% commission on gross proceeds; no obligation to sell shares.","Company may suspend or terminate sales at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174825,"accession_number":"0001193125-25-037586","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viridian reports positive phase 3 data for veligrotug in TED; cash $717.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Veligrotug met all primary and secondary endpoints in THRIVE and THRIVE-2 for active and chronic TED.","BLA submission on track for 2H 2025; MAA submission expected 1H 2026.","Cash, equivalents, and investments $717.6M as of Dec 31, 2024, funding operations into 2H 2027.","Net loss $269.9M for 2024 vs $237.7M in 2023; R&D expenses rose to $238.3M.","Appointed Radhika Tripuraneni as CMO, succeeding Thomas Ciulla who transitions to consultant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":302000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174824,"accession_number":"0001193125-25-004435","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Viridian Therapeutics promotes Seth Harmon to CFO effective Jan 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Seth Harmon, previously SVP of Finance and Accounting and Principal Financial Officer, appointed CFO effective Jan 1, 2025.","New base salary of $480,000 and target bonus of 40% of base salary.","Received equity awards: stock option with grant date value of $1,662,000 and RSUs with grant date value of $554,000.","Harmon's prior roles include CFO of BioNTech US subsidiary and VP of Finance at Neon Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191776,"accession_number":"0001193125-24-279021","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Viridian's veligrotug meets all primary & secondary endpoints in Phase 3 THRIVE-2 chronic TED trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proptosis responder rate 56% vs 8% placebo (48% adj, p<0.0001); 2.34mm mean reduction vs 0.46mm.","Diplopia response 56% vs 25% (p=0.0006); complete resolution 32% vs 14% (p=0.0152) in chronic patients.","54% of veligrotug patients achieved CAS 0 or 1 vs 24% placebo (p=0.006); overall responder rate 56% vs 7%.","Veligrotug well-tolerated; 94% completed treatment; 9.6% placebo-adjusted rate of hearing impairment.","BLA submission on track for H2 2025; $753M cash on hand provides runway into H2 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191775,"accession_number":"0001193125-24-255130","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Viridian Q3 net loss $76.7M; positive phase 3 TED data, VRDN-008 best-in-class NHP profile","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $76.7M vs $47.7M YoY; cash $753.2M, net proceeds $243.2M from Sep offering; runway into H2 2027.","Positive phase 3 THRIVE data for veligrotug in active TED; THRIVE-2 topline expected Dec 2024.","Initiated phase 3 REVEAL-1 and REVEAL-2 for VRDN-003; topline data anticipated H1 2026.","VRDN-008 NHP data: 3x half-life vs efgartigimod, 20% deeper IgG reduction; IND planned year-end 2025.","VRDN-006 IND submission by year-end 2024; proof-of-concept IgG reduction data in H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":230000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208254,"accession_number":"0001193125-24-218131","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Viridian Therapeutics raises ~$258.8M in public offering of common and Series B preferred stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["10,666,600 common shares at $18.75/share and 20,000 Series B non-voting convertible preferred shares at $1,250.06250/share offered.","Underwriters' option for 1,800,000 additional common shares exercised in full on September 12, 2024.","Aggregate gross proceeds approximately $258.8 million before underwriting discounts and expenses.","Net proceeds expected to fund operations into the second half of 2027.","Closing of the offering expected on September 13, 2024 under existing shelf registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208253,"accession_number":"0001193125-24-216321","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Viridian's veligrotug Phase 3 THRIVE meets all endpoints; 70% proptosis responder rate vs 5% placebo (p<0.0001)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proptosis responder rate 70% drug vs 5% placebo; mean reduction 2.9 mm vs 0.5 mm (p<0.0001).","Complete diplopia resolution 54% vs 12%; CAS 0/1 achieved by 64% vs 18% (both p<0.0001).","No treatment-related serious AEs; 5.5% placebo-adjusted hearing impairment rate; 4% discontinuation rate.","THRIVE-2 enrollment complete; topline data year-end 2024; BLA submission on track for 2H 2025.","Cash $571.4M as of June 30, 2024; runway into 2H 2026; VRDN-003 phase 3 REVEAL trials initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208252,"accession_number":"0001193125-24-196513","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viridian Q2 net loss $65M; THRIVE topline readout on track for Sept 2024; cash $571.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $65.0M in Q2 2024 vs $55.1M Q2 2023; cash balance $571.4M as of June 30, 2024.","THRIVE phase 3 (active TED) topline data for VRDN-001 expected September 2024.","THRIVE-2 (chronic TED) enrollment completed with 188 patients, exceeding 159 target; topline due year-end 2024.","REVEAL-1 and REVEAL-2 phase 3 trials for subcutaneous VRDN-003 to initiate August 2024; topline data H1 2026.","IND for VRDN-006 (FcRn inhibitor) on track for year-end 2024; NHP data for VRDN-008 expected H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":144000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208251,"accession_number":"0001193125-24-178820","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Viridian Therapeutics posts updated investor presentation on website","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated corporate presentation available on company website, dated July 2024.","No financial results, guidance changes, or material events disclosed in the filing.","Presentation likely covers pipeline updates and corporate strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225855,"accession_number":"0001193125-24-164461","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Viridian shareholders approve 2M share increase for equity plan; directors elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to 2016 equity plan approved (32.2M for, 24.3M against), adding 2M shares to reserve.","Class III directors Stephen Mahoney and Arlene M. Morris elected; Morris received 24.9M withheld votes.","Advisory vote on exec compensation passed: 32.8M for, 23.7M against.","Ratification of KPMG as independent auditor passed: 58.4M for, 31.7K against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225854,"accession_number":"0001193125-24-133770","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viridian Therapeutics Q1: THRIVE TED trial enrollment completed (113 pts); topline data Sept 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents, and short-term investments of $613.2M as of March 31, 2024, sufficient into H2 2026.","Net loss of $48.5M for Q1 2024, compared to $68.2M in Q1 2023.","THRIVE global phase 3 trial in active TED enrolled 113 patients (exceeded target of 90); topline data expected September 2024.","Positive FDA Type C meeting for VRDN-003 subcutaneous candidate; pivotal program on track to start mid-2024.","VRDN-006 FcRn inhibitor IND submission on track for year-end 2024; VRDN-008 NHP data expected H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225853,"accession_number":"0001193125-24-097728","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2024-04-16T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Viridian Therapeutics amends lease for new headquarters suite, extends term 5 years","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Fourth Amendment to Lease for 10,427 rentable sq ft at 221 Crescent St, Waltham, MA.","Base rent starts at $38,232/month in first year, escalating ~2% annually over extended term.","Tenant improvement allowance of up to $104,270; three-year extension option and right of first refusal granted.","Replaces prior lease of 10,956 sq ft in a different suite at the same address."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244959,"accession_number":"0001193125-24-047916","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viridian reports $645.7M cash, $237.7M net loss; VRDN-001 Phase 3 readouts mid-2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and short-term investments ~$645.7M as of Jan 31, 2024 (preliminary), extending runway into H2 2026.","Net loss for FY2023 was $237.7M vs $129.9M in 2022; R&D expenses rose to $159.8M.","VRDN-001 Phase 3 THRIVE topline data expected mid-2024; THRIVE-2 at year-end 2024.","VRDN-003 subcutaneous pivotal program expected to start mid-2024 pending regulatory alignment.","FcRn inhibitor VRDN-006 IND submission anticipated by year-end 2024; VRDN-008 NHP data H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":314000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244958,"accession_number":"0001193125-24-011355","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2024-01-19T23:59:59+00:00","items":["1.01","2.02","8.01","9.01"],"status":"ready","headline":"Viridian raises ~$150M in stock offering, reports $477M cash, outlines VRDN-003/001 trial timelines","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised ~$150M gross from 7.14M shares at $21.00; underwriters have 30-day option for 1.07M additional shares.","Preliminary cash and investments of $477.4M as of Dec 31, 2023; combined with offering expected to fund ops into H2 2026.","VRDN-003: global pivotal trials in active and chronic TED planned to start mid-2024 pending regulatory alignment.","VRDN-001: THRIVE Phase 3 topline in active TED expected mid-2024; THRIVE-2 chronic TED topline by year-end 2024.","BLA package for VRDN-001 to include THRIVE, THRIVE-2 studies and safety database of ~300 treated patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244957,"accession_number":"0001193125-24-003936","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Viridian promotes Tom Ciulla to CMO; details 2024 TED trial timelines and FcRn milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Thomas Ciulla promoted to CMO, succeeding Dr. Barrett Katz who becomes consultant; Dr. Katz receives severance and consulting fee.","Topline results from THRIVE Phase 3 (active TED) expected mid-2024; THRIVE-2 (chronic TED) by year-end 2024.","Subcutaneous VRDN-003 pivotal study expected to start mid-2024 pending regulatory alignment.","FcRn portfolio: VRDN-006 IND by year-end 2024; VRDN-008 NHP data in 2H 2024.","Inducement grant of 62,000 stock options to new employee outside equity plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262415,"accession_number":"0001193125-23-297131","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2023-12-18T23:59:59+00:00","items":["5.03","7.01","8.01","9.01"],"status":"ready","headline":"Viridian selects VRDN-003 as lead SC program for TED; half-life 40-50 days, pivotal mid-2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VRDN-003 showed extended half-life of 40-50 days, 4–5× longer than VRDN-001.","No serious adverse events; all treatment-related AEs were grade 1 (mild) and no antidrug antibodies detected.","Modeled dosing supports once-every-8-weeks (Q8W) schedule; Q4W and Q2W also predicted to achieve robust exposure.","VRDN-001 SC and VRDN-002 SC development deprioritized in favor of VRDN-003.","Global pivotal trials expected to begin mid-2024 pending regulatory alignment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262414,"accession_number":"0001193125-23-276007","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viridian Q3 net loss $47.7M; new CEO Mahoney; cash runway into 2026 after $185M placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $47.7M vs $28.9M YoY; R&D $30.4M (+$8.3M) and G&A $20.9M (+$12.0M).","Cash, equivalents & ST investments $313M at Sep 30; closed $185M private placement Nov 1 extending runway into 2026.","Stephen Mahoney appointed President/CEO in Oct; new COO Thomas Beetham and CBO Shan Wu also hired.","THRIVE (active TED) and THRIVE-2 (chronic) Phase 3 trials on track; topline mid-2024 and year-end 2024 respectively.","Subcutaneous program selection by year-end 2023; Phase 1 data for VRDN-001/002/003 expected Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":242000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262413,"accession_number":"0001193125-23-269415","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Director Scott Myers resigns from Viridian board; company adopts amended bylaws effective Nov 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Myers resigned from the board effective Oct 29, 2023; departure not due to any disagreement with the company.","Board adopted Third Amended and Restated Bylaws effective Nov 1, 2023.","Bylaws modify notice period required to call a special meeting of the Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262412,"accession_number":"0001193125-23-265717","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2023-10-30T23:59:59+00:00","items":["1.01","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Viridian Therapeutics announces new CEO, $185M private placement, next-gen FcRn inhibitors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stephen Mahoney appointed President and CEO, succeeds Scott Myers. Base salary $650k, 55% bonus target, option for 1.26M shares.","$185M private placement: 8.79M shares at $12.38, plus 92,312 convertible preferred shares. Closing expected Nov 1, 2023.","Discloses preclinical FcRn inhibitors VRDN-006 and VRDN-008; first IND filing by year-end 2024. Targets autoimmune diseases.","TED pipeline: subcutaneous program selection by end 2023; VRDN-001 THRIVE Phase 3 active TED readout mid-2024.","Thomas Beetham appointed COO; base salary $500k, 45% bonus target, option for 474k shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279602,"accession_number":"0001193125-23-240931","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2023-09-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Viridian appoints Agios CMO Dr. Sarah Gheuens to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 5 to 6 directors; Gheuens appointed Class I director until 2025 annual meeting.","Also appointed to Science and Technology Committee.","Compensation: $46,000 annual retainer and option for 40,000 shares vesting over 3 years.","Gheuens is CMO of Agios Pharmaceuticals (AGIO) and previously held roles at Biogen (BIIB).","No arrangements, family relationships, or material interests requiring disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279601,"accession_number":"0001193125-23-233500","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2023-09-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Viridian Therapeutics CFO Kristian Humer resigns; Seth Harmon appointed principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kristian Humer, CFO and CBO, resigns effective Sept 12, 2023; eligible for severance under existing agreement.","Seth Harmon, SVP of Finance (joined May 2023), assumes role of principal financial and accounting officer.","Harmon's base salary increased to $410,000; entitled to 12-month severance upon involuntary termination.","Harmon previously CFO of BioNTech US subsidiary and held finance roles at Neon Therapeutics and Merrimack.","Harmon is a CPA with prior experience at Ernst & Young."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279600,"accession_number":"0001193125-23-187636","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2023-07-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Viridian posts updated investor presentation on website; contents not detailed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation dated July 2023 titled 'Corporate Overview' made available via 8-K.","No financial results, pipeline milestones, or guidance revisions disclosed in the filing excerpt.","Company stated presentation was posted under Regulation FD; no material new facts provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279599,"accession_number":"0001193125-23-184757","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2023-07-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Viridian announces positive Phase 1/2 data for VRDN-001 in chronic TED; THRIVE trial amended","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VRDN-001 showed mean proptosis reduction of 1.6 mm (combined doses) at week 6; proptosis responder rate 42%.","No serious adverse events, hearing impairment, or hyperglycemia reported in chronic TED patients.","THRIVE Phase 3 trial amended to 5-dose regimen; topline results expected mid-2024.","THRIVE-2 Phase 3 in chronic TED to start Q3 2023; topline results expected by year-end 2024.","IND filed for VRDN-003 and VRDN-001 SC; lead SC candidate selection expected by year-end 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298007,"accession_number":"0001193125-23-169038","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Viridian shareholders approve 2M share increase to 2016 Equity Plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2016 Equity Incentive Plan, increasing share reserve by 2,000,000 shares.","Elected Tomas Kiselak and Jennifer K. Moses as Class II directors to serve until 2026.","Ratified KPMG as independent auditor for 2023 with 39,588,463 votes for.","Advisory vote on NEO compensation passed with 22,946,964 for and 12,351,317 against.","Total shares outstanding as of record date: 43,108,897."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298006,"accession_number":"0001193125-23-139409","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viridian Therapeutics Q1 net loss $68.2M; VRDN-001 chronic TED data expected June/July 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $68.2M for Q1 2023 vs. $25.7M in Q1 2022; R&D expenses $50.7M including $15M upfront to Enable Injections.","Cash and short-term investments $373.9M at March 31, 2023, down from $424.6M at Dec 31, 2022; expected to fund into H2 2025.","Topline data from VRDN-001 proof-of-concept study in chronic TED expected June/July 2023; THRIVE-2 Phase 3 initiation planned mid-2023.","Lead subcutaneous (SC) program selection expected year-end 2023; IND for VRDN-003 to be filed Q2 2023.","Appointed Tony Casciano as CCO, Thomas Ciulla as CDO, and other senior executives during Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":98000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298005,"accession_number":"0001193125-23-098482","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2023-04-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Viridian Therapeutics COO Carrie Melvin departs effective April 11, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carrie Melvin ceased as COO effective April 11, 2023; severance benefits provided per employment agreement.","Severance treated as involuntary not-for-cause termination, subject to release and restrictive covenants.","No replacement named in the filing; succession plans not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318256,"accession_number":"0001193125-23-067504","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Viridian Therapeutics discloses de minimis cash holdings at Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company holds low single digit millions of USD in cash and equivalents at Silicon Valley Bank.","Disclosure made on March 10, 2023, amid SVB's collapse.","Amount is described as de minimis, indicating limited exposure.","Item 7.01 Regulation FD Disclosure filed with SEC as an 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318255,"accession_number":"0001193125-23-063737","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2023-03-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viridian Q4 2022 net loss $45.8M, cash $424.6M; THRIVE Ph3 enrolled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $45.8M in Q4 2022 vs $28.9M in Q4 2021; R&D expense $39.3M vs $22.4M.","Cash, equivalents & short-term investments $424.6M as of Dec 31, 2022; runway into H2 2025.","First patient enrolled in THRIVE Phase 3 trial of VRDN-001 for active TED; topline mid-2024.","Initial proof-of-concept data for VRDN-001 in chronic TED expected Q2 2023.","Appointed Scott Myers as President and CEO in February 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318254,"accession_number":"0001193125-23-024877","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2023-02-06T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Viridian Therapeutics appoints Scott Myers as President and CEO, succeeding Jonathan Violin","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Myers, former CEO of AMAG Pharmaceuticals, appointed President & CEO and Class III Director effective Feb 6, 2023.","Founding CEO Jonathan Violin steps down; receives 18-month salary severance, 12-month accelerated option vesting, and consulting role.","Myers granted inducement award of 1,000,000 stock options and 250,000 RSUs, vesting over 4 years with first cliff at 12 months.","Company references positive topline data from Phase 1/2 trial of VRDN-001 for thyroid eye disease (previously filed presentation)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318253,"accession_number":"0001193125-23-004046","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Viridian reports positive Phase 1/2 data for VRDN-001 in thyroid eye disease; 71% proptosis responders across doses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["3 mg/kg cohort: 67% proptosis responders, 56% overall responders, 67% achieved CAS 0/1, 20% complete diplopia resolution at week 6.","Across all 21 drug-treated patients: 71% proptosis responders, 67% overall responders, 62% CAS 0/1, 54% complete diplopia resolution.","No serious adverse events, discontinuations, or infusion reactions reported with VRDN-001 across dose levels.","Low-dose data support once-monthly subcutaneous dosing profile for VRDN-002 and VRDN-003; VRDN-003 IND planned Q2 2023.","Phase 3 THRIVE trial enrollment ongoing; results expected mid-2024; chronic TED proof-of-concept data expected H1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1763530000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-01-09T23:59:59+00:00|318253"}